"Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026" Report Highlights:
Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
Global Bispecific Antibody Pipeline: 333 Drug
Commercially Available Bispecific Antibodies: 2 (Blincyto and Hemlibra)
Hemlibra Sales and Market Share 2019: > US$ 1.4 Billion and > 80%
“Global Bispecific Antibody Market Opportunity, Drug Sales and Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global bispecific antibodies market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on two (Blincyto and Hemlibra) commercially available bispecific antibodies with their regional level revenue, market share and the clinical profile.
"Since Commercially Launch In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019"
The availability of the bispecific antibodies in the market and the revenue generated by the drugs in short span of four years (since commercialization in 2015) clearly depicts the current dominant trends followed by its characterization as a next generation of antibody therapy. The number of the investigational agents under preclinical and clinical trials all around the globe adds as a major key component for the establishment of the antibody therapy as a one stop treatment for all the disease.
Pharmaceutical companies involved in the development of these promising bispecific antibodies molecules strongly believe that their products are superior to first generation nonspecific antibody products. No doubt they are adamant to their viewpoint that bispecific antibodies will be more potent against disease targets, which includes combating more than one aspect of the disease simultaneously, better and cheaper production with least side effects. The molecules are also said to have the potential of dealing with multiple disease with a single agent making them more important.
“Structural Diversity Among The Antibodies Are Opening A Wide Plethora For The Novel Bispecific Antibody Agents, And Thus Providing A Great Opportunity For Establishing A Superior Market In The Future.”
Bispecific antibodies are not only being developed for the oncological use but also the non oncological which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. Their vitality if approved can also make them a great tool in the diagnostics tests detect and monitor infectious agents like HIV, the cause of AIDS, or the influenza virus causing pandemic flu and for identifying diseases released by biological weapons such as smallpox and anthrax. In addition, monoclonal antibodies have also helped in checks for salmonella and bacteria that cause food poisoning. The global opportunity value of the bispecific antibody market is estimated to be approximately US$ 10 billion per year, which is expected to be achieved in next five year timeframe.
Introduction to Bispecific Monoclonal Antibody
1.1 Overview of Monoclonal Antibody
1.2 Overview of Bispecific Monoclonal Antibody
1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies
The Engineering and Development of Bispecific Antibodies
Figure 5-4: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto and Hemlibra) , 2018 and 2019
Figure 5-5: Global – Bispecific Antibody Market Share(%) by Products (Blincyto and Hemlibra) , 2018
Figure 5-6: Global – Bispecific Antibody Market Share(%) by Products (Blincyto and Hemlibra) , 2019
Figure 5-7: Global – Bispecific Antibody Quarterly Sales (US$ Million), by Products (Blincyto and Hemlibra), 2019
Figure 6-1: Blincyto – Recommended Number of Induction and Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, December’2019
Figure 6-2: Blincyto – Duration of Treatment Phase and Resting Phase in Induction and Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , December’2019
Figure 6-3: Blincyto – Cost of Single Cycle and Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), December’2019
Figure 6-4: Blincyto – Recommended Number of Induction and Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, December’2019
Figure 6-5: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle and Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), December’2019
Figure 6-6: Blincyto – Cost of 1st and 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), December’2019
Figure 6-7: Blincyto – Cost of Different Treatment Phases and Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), December’2019
Figure 6-8: Hemlibra – Cost for Single Unit of 30mcg and 150mcg Subcutaneous Injection (US$), December’2019
Figure 6-9: Hemlibra – Recommended Loading and Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week), December’2019
Figure 6-10: Hemlibra – Average Monthly and Annual Cost for Treatment of Hemophilia A (US$), December’2019
